(Q46381951)

21 December 2017

title

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes (English)

1 reference

21 December 2017

0 references

2

1 reference

21 December 2017

author name string

H-J Mest

series ordinal

1

1 reference

21 December 2017

publication date

16 March 2005

1 reference

21 December 2017

published in

Diabetologia

1 reference

21 December 2017

volume

48

1 reference

21 December 2017

issue

4

1 reference

21 December 2017

page(s)

616-620

1 reference

21 December 2017

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

cites work

1 reference

12 December 2020

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

12 December 2020

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

12 December 2020

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

12 December 2020

Restoration of first-phase insulin secretion by the imidazoline compound LY374284 in pancreatic islets of diabetic db/db mice

1 reference

12 December 2020

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

12 December 2020

Cell-surface peptidases

1 reference

12 December 2020

Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.

1 reference

12 December 2020

Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

1 reference

12 December 2020

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

12 December 2020

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

12 December 2020

Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.

1 reference

12 December 2020

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

1 reference

12 December 2020

Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties

1 reference

12 December 2020

10.1007/S00125-005-1707-5

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017